Alenura Delivers Positive Phase 2 Results in Interstitial Cystitis/Bladder Pain Syndrome Trial

New Brunswick, New Jersey--(Newsfile Corp. - November 9, 2026) - Vaneltix Pharma, Inc. ("Vaneltix"), a biotechnology company focused on developing treatments addressing unmet needs in women's healthcare and urology and Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) ("Hyloris") , the specialty pharma group committed to addressing unmet medical needs through reinventing existing medicines and smart NCE developments, today announce positive and statistically significant Phase 2 efficacy...

2026-11-09 7:00 AM EST